Bristol Myers Squibb
Investor profile
Corporate
Also recorded as: Bristol Myers-Squibb
Deals
7
distinct rounds
Companies
7
backed
Active span
2018–2025
8 yrs
Total round €
€456M
sum of rounds joined
Deals by year
distinct rounds / yearTop sectors
by dealsStages
by dealsCountries
by dealsCo-investment network
shared roundsHover a node for shared-deal counts; click a co-investor to open its profile.
Frequent co-investors
shared rounds- Sunstone Capital2
- 5AM Ventures1
- Agent Capital1
- BioMedPartners1
- Bpifrance Large Venture1
- Catalio Capital Management1
- Coparion1
- DNS Capital1
- FundPlus1
- Hadean Ventures1
- HBM Healthcare Investments1
- High-Tech Gründerfonds1
- INKEF Capital1
- Leonard Green & Partners1
- LifeArc Ventures1
- Lifeforce Capital1
- LSP1
- M Ventures1
- Magnetic Ventures1
- Maverick Ventures1
- MP Healthcare Venture Management1
- Northpond Ventures1
- Novo Holdings1
- Novo Seeds1
- OrbiMed1
Portfolio
top 30 by total round €| Company | Country | Rounds | Total € |
|---|---|---|---|
| GlycoEra | Switzerland | 1 | €114M |
| Galecto Biotech | Denmark | 1 | €79M |
| Owkin | France | 1 | €75M |
| Cardior Pharmaceuticals | Germany | 1 | €64M |
| TreeFrog Therapeutics | France | 1 | €64M |
| Transition Bio | UK | 1 | €47M |
| IMIDomics | Spain | 1 | €14M |
Biggest deals
top 10 by amount| Company | Stage | Amount | Date |
|---|---|---|---|
| GlycoEra | Series B | €114M | 2025-05 |
| Galecto Biotech | Series C | €79M | 2018-09 |
| Owkin | Series B | €75M | 2022-06 |
| Cardior Pharmaceuticals | Series B | €64M | 2021-08 |
| TreeFrog Therapeutics | Series B | €64M | 2021-09 |
| Transition Bio | Series A | €47M | 2022-06 |
| IMIDomics | Other | €14M | 2021-07 |